• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance

    2/6/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email
    • Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year
    • GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year
    • Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year
    • GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year
    • Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year
    • R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x
    • R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency
    • TAS Revenue of $1,658 million for the fourth quarter, up 9.5 percent compared to the fourth quarter of 2023, $6,160 million for the full year, up 5.7 percent year-over-year, both at constant currency
    • Operating Cash Flow of $885 million, bringing full-year Operating Cash Flow to $2,716 million, up 26 percent year-over-year
    • Free Cash Flow of $721 million, bringing full-year Free Cash Flow to $2,114 million, up 41 percent year-over-year
    • Reaffirms 2025 outlook of revenue growth at constant currency ex-COVID of 4 to 7 percent, Adjusted EBITDA margin expansion of up to 20 basis points and Adjusted Diluted Earnings per Share growth of 5 to 9 percent
    • Full-year 2025 Revenue guidance of $15,725 million to $16,125 million, Adjusted EBITDA of $3,765 million to $3,885 million and Adjusted Diluted Earnings per Share of $11.70 to $12.10

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2024.

    "IQVIA delivered excellent fourth quarter performance, closing out a strong 2024," said Ari Bousbib, chairman and CEO of IQVIA. "R&DS revenue was on target and bookings exceeded our expectations despite the choppy CRO market environment. TAS revenue was above target and momentum continues to build into 2025. For the full year, we delivered margin expansion, high single-digit growth in Adjusted EPS, and outstanding free cash flow; we also repurchased $1.35 billion dollars of our shares while lowering our net leverage ratio year-over-year. We are reaffirming the 2025 guidance we provided at our December Investor Day."

    Fourth-Quarter 2024 Operating Results

    Revenue for the fourth quarter of $3,958 million increased 2.3 percent on a reported basis and 3.0 percent at constant currency, compared to the fourth quarter of 2023. Technology & Analytics Solutions (TAS) revenue of $1,658 million grew 8.3 percent on a reported basis and 9.5 percent at constant currency. Research & Development Solutions (R&DS) revenue of $2,123 million decreased 1.3 percent on a reported basis and 1.0 percent at constant currency. Excluding the impact of pass throughs, R&DS revenue grew 2.5 percent year-over-year on a reported basis. Contract Sales & Medical Solutions (CSMS) revenue of $177 million decreased 4.8 percent on a reported basis and 3.2 percent at constant currency.

    As of December 31, 2024, R&DS contracted backlog, including reimbursed expenses, was $31.1 billion, growing 4.4 percent year-over-year and 5.5 percent at constant currency. The company expects approximately $7.9 billion of this backlog to convert to revenue in the next twelve months. The fourth-quarter book-to-bill ratio was 1.20x, resulting in a trailing-twelve-month book-to-bill ratio of 1.19x.

    Fourth-quarter GAAP Net Income was $437 million, down 6.8 percent year-over-year, and GAAP Diluted Earnings per Share was $2.42, declining 4.7 percent year-over-year. Adjusted Net Income was $564 million, up 7.8 percent year-over-year, and Adjusted Diluted Earnings per Share was $3.12, up 9.9 percent year-over-year. Adjusted EBITDA was $996 million, increasing 3.1 percent year-over-year.

    Full-Year 2024 Operating Results

    Revenue of $15,405 million for the full year of 2024 grew 2.8 percent on a reported basis and 3.4 percent at constant currency, compared to 2023. TAS revenue was $6,160 million, up 5.1 percent on a reported basis and 5.7 percent at constant currency. R&DS revenue was $8,527 million, up 1.6 percent on a reported basis and 2.0 percent at constant currency. CSMS revenue was $718 million, down 1.2 percent on a reported basis and up 1.4 percent at constant currency.

    For the full year of 2024, GAAP Net Income was $1,373 million, up 1.1 percent year-over-year, and GAAP Diluted Earnings per Share was $7.49, up 2.7 percent year-over-year. Adjusted Net Income was $2,042 million, increasing 7.4 percent year-over-year, and Adjusted Diluted Earnings per Share was $11.13, up 9.1 percent year-over-year. Adjusted EBITDA for the full year of 2024 was $3,684 million, up 3.2 percent year-over-year.

    Financial Position

    As of December 31, 2024, cash and cash equivalents were $1,702 million and debt was $13,983 million, resulting in net debt of $12,281 million, and IQVIA's Net Leverage Ratio was 3.33x trailing twelve-month Adjusted EBITDA. For the fourth quarter of 2024, Operating Cash Flow was $885 million and Free Cash Flow was $721 million. For the full year of 2024, Operating Cash Flow was $2,716 million and Free Cash Flow was $2,114 million, growing 26 percent and 41 percent year-over-year, respectively.

    Share Repurchase

    During the fourth quarter of 2024, the company repurchased $1,150 million of its common stock, resulting in full-year share repurchases of $1,350 million. IQVIA had $1,013 million of share repurchase authorization remaining as of December 31, 2024. On February 5, 2025, the IQVIA board of directors increased the share repurchase authorization by $2,000 million dollars, bringing the total remaining authorization to $3,013 million.

    Full-Year 2025 Guidance

    The company reaffirms its 2025 outlook of revenue growth at constant currency ex-COVID of 4 to 7 percent, Adjusted EBITDA margin expansion of up to 20 basis points and Adjusted Diluted Earnings per Share growth of 5 to 9 percent. These expectations result in full-year revenue guidance of $15,725 million to $16,125 million, Adjusted EBITDA of $3,765 million to $3,885 million, and Adjusted Diluted Earnings per Share of $11.70 to $12.10.

    This revenue guidance assumes just over $100 million of COVID-related revenue step-down, entirely in R&DS, approximately 150 basis points of headwind from foreign exchange, and 100-150 basis points of contribution from acquisitions.

    All financial guidance assumes foreign currency exchange rates as of February 5, 2025 remain in effect for the forecast period.

    Webcast & Conference Call Details

    IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its fourth-quarter and full-year 2024 results and first-quarter and full-year 2025 guidance. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants connect to the call using the information provided in the confirmation email and will be placed directly into the call.

    About IQVIA

    IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance, and patient safety. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

    IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

    Cautionary Statements Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our full-year 2025 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "assume," "anticipate," "intend," "plan," "forecast," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, and international conflicts or other disruptions outside of our control; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or future changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners' security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; government regulators or our customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions, inflation, and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to our business, see the "Risk Factors" in our annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

    Note on Non-GAAP Financial Measures

    This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted Earnings per Share, Gross Leverage Ratio, Net Leverage Ratio and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the company's financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company's financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company's results of operations as determined in accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, the company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements, trademarks and trade names from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

    The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. Our full-year 2025 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. For the same reasons, the company is unable to address the probable significance of the unavailable information. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based compensation and other items not reflective of the company's ongoing operations.

    Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company's results of operations as determined in accordance with GAAP.

    IQVIAFIN

    Table 1

    IQVIA HOLDINGS INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF INCOME

    (preliminary and unaudited)

     

     

     

    Three Months Ended December 31,

     

    Twelve Months Ended December 31,

    (in millions, except per share data)

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Revenues

     

    $

    3,958

     

     

    $

    3,868

     

     

    $

    15,405

     

     

    $

    14,984

     

    Cost of revenues, exclusive of depreciation and amortization

     

     

    2,580

     

     

     

    2,478

     

     

     

    10,030

     

     

     

    9,745

     

    Selling, general and administrative expenses

     

     

    453

     

     

     

    556

     

     

     

    1,992

     

     

     

    2,053

     

    Depreciation and amortization

     

     

    303

     

     

     

    316

     

     

     

    1,114

     

     

     

    1,125

     

    Restructuring costs

     

     

    (4

    )

     

     

    17

     

     

     

    67

     

     

     

    84

     

    Income from operations

     

     

    626

     

     

     

    501

     

     

     

    2,202

     

     

     

    1,977

     

    Interest income

     

     

    (11

    )

     

     

    (12

    )

     

     

    (47

    )

     

     

    (36

    )

    Interest expense

     

     

    171

     

     

     

    181

     

     

     

    670

     

     

     

    672

     

    Loss on extinguishment of debt

     

     

    —

     

     

     

    6

     

     

     

    —

     

     

     

    6

     

    Other income, net

     

     

    (78

    )

     

     

    (47

    )

     

     

    (90

    )

     

     

    (124

    )

    Income before income taxes and equity in earnings (losses) of unconsolidated affiliates

     

     

    544

     

     

     

    373

     

     

     

    1,669

     

     

     

    1,459

     

    Income tax expense (benefit)

     

     

    112

     

     

     

    (102

    )

     

     

    301

     

     

     

    101

     

    Income before equity in earnings (losses) of unconsolidated affiliates

     

     

    432

     

     

     

    475

     

     

     

    1,368

     

     

     

    1,358

     

    Equity in earnings (losses) of unconsolidated affiliates

     

     

    5

     

     

     

    (6

    )

     

     

    5

     

     

     

    —

     

    Net income

     

    $

    437

     

     

    $

    469

     

     

    $

    1,373

     

     

    $

    1,358

     

    Earnings per share attributable to common stockholders:

     

     

     

     

     

     

     

     

    Basic

     

    $

    2.44

     

     

    $

    2.58

     

     

    $

    7.57

     

     

    $

    7.39

     

    Diluted

     

    $

    2.42

     

     

    $

    2.54

     

     

    $

    7.49

     

     

    $

    7.29

     

    Weighted average common shares outstanding:

     

     

     

     

     

     

     

     

    Basic

     

     

    178.9

     

     

     

    181.9

     

     

     

    181.3

     

     

     

    183.8

     

    Diluted

     

     

    180.8

     

     

     

    184.3

     

     

     

    183.4

     

     

     

    186.3

     

    Table 2

    IQVIA HOLDINGS INC. AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

    (preliminary and unaudited)

     

     

     

    December 31,

    (in millions, except per share data)

     

     

    2024

     

     

     

    2023

     

    ASSETS

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    1,702

     

     

    $

    1,376

     

    Trade accounts receivable and unbilled services, net

     

     

    3,204

     

     

     

    3,381

     

    Prepaid expenses

     

     

    154

     

     

     

    141

     

    Income taxes receivable

     

     

    36

     

     

     

    32

     

    Investments in debt, equity and other securities

     

     

    141

     

     

     

    120

     

    Other current assets and receivables

     

     

    592

     

     

     

    546

     

    Total current assets

     

     

    5,829

     

     

     

    5,596

     

    Property and equipment, net

     

     

    535

     

     

     

    523

     

    Operating lease right-of-use assets

     

     

    238

     

     

     

    296

     

    Investments in debt, equity and other securities

     

     

    108

     

     

     

    105

     

    Investments in unconsolidated affiliates

     

     

    266

     

     

     

    134

     

    Goodwill

     

     

    14,710

     

     

     

    14,567

     

    Other identifiable intangibles, net

     

     

    4,499

     

     

     

    4,839

     

    Deferred income taxes

     

     

    194

     

     

     

    166

     

    Deposits and other assets, net

     

     

    520

     

     

     

    455

     

    Total assets

     

    $

    26,899

     

     

    $

    26,681

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

    Current liabilities:

     

     

     

     

    Accounts payable and accrued expenses

     

    $

    3,684

     

     

    $

    3,564

     

    Unearned income

     

     

    1,779

     

     

     

    1,799

     

    Income taxes payable

     

     

    156

     

     

     

    116

     

    Current portion of long-term debt

     

     

    1,145

     

     

     

    718

     

    Other current liabilities

     

     

    193

     

     

     

    294

     

    Total current liabilities

     

     

    6,957

     

     

     

    6,491

     

    Long-term debt, less current portion

     

     

    12,838

     

     

     

    12,955

     

    Deferred income taxes

     

     

    196

     

     

     

    202

     

    Operating lease liabilities

     

     

    173

     

     

     

    223

     

    Other liabilities

     

     

    668

     

     

     

    698

     

    Total liabilities

     

     

    20,832

     

     

     

    20,569

     

    Stockholders' equity:

     

     

     

     

    Common stock and additional paid-in capital, 400.0 shares authorized as of December 31, 2024 and 2023, $0.01 par value, 258.2 shares issued and 176.1 shares outstanding as of December 31, 2024; 257.2 shares issued and 181.5 shares outstanding as of December 31, 2023

     

     

    11,143

     

     

     

    11,028

     

    Retained earnings

     

     

    6,065

     

     

     

    4,692

     

    Treasury stock, at cost, 82.1 and 75.7 shares as of December 31, 2024 and 2023, respectively

     

     

    (10,103

    )

     

     

    (8,741

    )

    Accumulated other comprehensive loss

     

     

    (1,038

    )

     

     

    (867

    )

    Total stockholders' equity

     

     

    6,067

     

     

     

    6,112

     

    Total liabilities and stockholders' equity

     

    $

    26,899

     

     

    $

    26,681

     

    Table 3

    IQVIA HOLDINGS INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (preliminary and unaudited)

     

     

     

    Year Ended December 31,

    (in millions)

     

     

    2024

     

     

     

    2023

     

    Operating activities:

     

     

     

     

    Net income

     

    $

    1,373

     

     

    $

    1,358

     

    Adjustments to reconcile net income to cash provided by operating activities:

     

     

     

     

    Depreciation and amortization

     

     

    1,114

     

     

     

    1,125

     

    Amortization of debt issuance costs and discount

     

     

    21

     

     

     

    18

     

    Stock-based compensation

     

     

    206

     

     

     

    217

     

    Earnings from unconsolidated affiliates

     

     

    (5

    )

     

     

    —

     

    Gain on investments, net

     

     

    (22

    )

     

     

    (20

    )

    Benefit from deferred income taxes

     

     

    (129

    )

     

     

    (269

    )

    Changes in operating assets and liabilities:

     

     

     

     

    Accounts receivable and unbilled services

     

     

    182

     

     

     

    (388

    )

    Prepaid expenses and other assets

     

     

    7

     

     

     

    34

     

    Accounts payable and accrued expenses

     

     

    115

     

     

     

    267

     

    Unearned income

     

     

    9

     

     

     

    (29

    )

    Income taxes payable and other liabilities

     

     

    (155

    )

     

     

    (164

    )

    Net cash provided by operating activities

     

     

    2,716

     

     

     

    2,149

     

    Investing activities:

     

     

     

     

    Acquisition of property, equipment and software

     

     

    (602

    )

     

     

    (649

    )

    Acquisition of businesses, net of cash acquired

     

     

    (735

    )

     

     

    (876

    )

    Purchases of marketable securities, net

     

     

    —

     

     

     

    (6

    )

    Investments in unconsolidated affiliates, net of payments received

     

     

    (132

    )

     

     

    (39

    )

    Investments in debt and equity securities

     

     

    (2

    )

     

     

    (38

    )

    Proceeds from sale of property, equipment and software

     

     

    25

     

     

     

    —

     

    Other

     

     

    2

     

     

     

    5

     

    Net cash used in investing activities

     

     

    (1,444

    )

     

     

    (1,603

    )

    Financing activities:

     

     

     

     

    Proceeds from issuance of debt

     

     

    —

     

     

     

    4,000

     

    Payment of debt issuance costs

     

     

    (1

    )

     

     

    (50

    )

    Repayment of debt and principal payments on finance leases

     

     

    (172

    )

     

     

    (2,873

    )

    Proceeds from revolving credit facility

     

     

    1,685

     

     

     

    2,384

     

    Repayment of revolving credit facility

     

     

    (960

    )

     

     

    (2,709

    )

    Payments related to employee stock option plans

     

     

    (64

    )

     

     

    (61

    )

    Repurchase of common stock

     

     

    (1,350

    )

     

     

    (992

    )

    Contingent consideration and deferred purchase price payments

     

     

    (16

    )

     

     

    (81

    )

    Net cash used in financing activities

     

     

    (878

    )

     

     

    (382

    )

    Effect of foreign currency exchange rate changes on cash

     

     

    (68

    )

     

     

    (4

    )

    Increase in cash and cash equivalents

     

     

    326

     

     

     

    160

     

    Cash and cash equivalents at beginning of period

     

     

    1,376

     

     

     

    1,216

     

    Cash and cash equivalents at end of period

     

    $

    1,702

     

     

    $

    1,376

     

    Table 4

    IQVIA HOLDINGS INC. AND SUBSIDIARIES

    NET INCOME TO ADJUSTED EBITDA RECONCILIATION

    (preliminary and unaudited)

     

     

     

    Three Months Ended December 31,

     

    Twelve Months Ended December 31,

    (in millions)

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net Income

     

    $

    437

     

     

    $

    469

     

     

    $

    1,373

     

     

    $

    1,358

     

    Provision for (benefit from) income taxes (1)

     

     

    112

     

     

     

    (102

    )

     

     

    301

     

     

     

    101

     

    Depreciation and amortization

     

     

    303

     

     

     

    316

     

     

     

    1,114

     

     

     

    1,125

     

    Interest expense, net

     

     

    160

     

     

     

    169

     

     

     

    623

     

     

     

    636

     

    (Income) loss in unconsolidated affiliates

     

     

    (5

    )

     

     

    6

     

     

     

    (5

    )

     

     

    —

     

    Stock-based compensation

     

     

    48

     

     

     

    45

     

     

     

    206

     

     

     

    217

     

    Other income, net (2)

     

     

    (74

    )

     

     

    (40

    )

     

     

    (63

    )

     

     

    (132

    )

    Loss on extinguishment of debt

     

     

    —

     

     

     

    6

     

     

     

    —

     

     

     

    6

     

    Restructuring and related expenses (3)

     

     

    7

     

     

     

    24

     

     

     

    106

     

     

     

    126

     

    Acquisition related expenses

     

     

    8

     

     

     

    73

     

     

     

    29

     

     

     

    132

     

    Adjusted EBITDA

     

    $

    996

     

     

    $

    966

     

     

    $

    3,684

     

     

    $

    3,569

     

    (1)

    Three and Twelve months ended December 31, 2023 include a $125M tax benefit due to an internal legal entity restructuring.

    (2)

    Reflects certain non-operating income items, revaluations of contingent consideration and certain non-recurring expenses.

    (3)

    Reflects restructuring costs as well as accelerated expenses related to lease exits.

    Table 5

    IQVIA HOLDINGS INC. AND SUBSIDIARIES

    NET INCOME TO ADJUSTED NET INCOME RECONCILIATION

    (preliminary and unaudited)

     

     

     

    Three Months Ended December 31,

     

    Twelve Months Ended December 31,

    (in millions, except per share data)

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net Income

     

    $

    437

     

     

    $

    469

     

     

    $

    1,373

     

     

    $

    1,358

     

    Provision for (benefit from) income taxes (1)

     

     

    112

     

     

     

    (102

    )

     

     

    301

     

     

     

    101

     

    Purchase accounting amortization (2)

     

     

    138

     

     

     

    149

     

     

     

    539

     

     

     

    560

     

    (Income) loss in unconsolidated affiliates

     

     

    (5

    )

     

     

    6

     

     

     

    (5

    )

     

     

    —

     

    Stock-based compensation

     

     

    48

     

     

     

    45

     

     

     

    206

     

     

     

    217

     

    Other income, net (3)

     

     

    (74

    )

     

     

    (40

    )

     

     

    (63

    )

     

     

    (132

    )

    Loss on extinguishment of debt

     

     

    —

     

     

     

    6

     

     

     

    —

     

     

     

    6

     

    Restructuring and related expenses (4)

     

     

    25

     

     

     

    34

     

     

     

    124

     

     

     

    136

     

    Acquisition related expenses

     

     

    8

     

     

     

    73

     

     

     

    29

     

     

     

    132

     

    Adjusted Pre Tax Income

     

    $

    689

     

     

    $

    640

     

     

    $

    2,504

     

     

    $

    2,378

     

    Adjusted tax expense

     

     

    (125

    )

     

     

    (117

    )

     

     

    (462

    )

     

     

    (477

    )

    Adjusted Net Income

     

    $

    564

     

     

    $

    523

     

     

    $

    2,042

     

     

    $

    1,901

     

     

     

     

     

     

     

     

     

     

    Adjusted earnings per share attributable to common stockholders:

     

     

     

     

     

     

     

     

    Basic

     

    $

    3.15

     

     

    $

    2.88

     

     

    $

    11.26

     

     

    $

    10.34

     

    Diluted

     

    $

    3.12

     

     

    $

    2.84

     

     

    $

    11.13

     

     

    $

    10.20

     

    Weighted average common shares outstanding:

     

     

     

     

     

     

     

     

    Basic

     

     

    178.9

     

     

     

    181.9

     

     

     

    181.3

     

     

     

    183.8

     

    Diluted

     

     

    180.8

     

     

     

    184.3

     

     

     

    183.4

     

     

     

    186.3

     

    (1)

    Three and Twelve months ended December 31, 2023 include a $125M tax benefit due to an internal legal entity restructuring; the benefit is excluded from Adjusted tax expense.

    (2)

    Reflects all the amortization of acquired intangible assets.

    (3)

    Reflects certain non-operating income items, revaluations of contingent consideration and certain non-recurring expenses.

    (4)

    Reflects restructuring costs as well as accelerated expenses related to lease exits and asset abandonments.

    Table 6

    IQVIA HOLDINGS INC. AND SUBSIDIARIES

    NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW RECONCILIATION

    (preliminary and unaudited)

     

    (in millions)

     

    Three Months Ended December 31, 2024

     

    Twelve Months Ended December 31, 2024

    Net Cash provided by Operating Activities

     

    $

    885

     

     

    $

    2,716

     

    Acquisition of property, equipment and software

     

     

    (164

    )

     

     

    (602

    )

    Free Cash Flow

     

    $

    721

     

     

    $

    2,114

     

    Table 7

    IQVIA HOLDINGS INC. AND SUBSIDIARIES

    CALCULATION OF GROSS AND NET LEVERAGE RATIOS

    AS OF DECEMBER 31, 2024

    (preliminary and unaudited)

     

    (in millions)

     

     

    Gross Debt, net of Unamortized Discount and Debt Issuance Costs, as of December 31, 2024

     

    $

    13,983

    Net Debt as of December 31, 2024

     

    $

    12,281

    Adjusted EBITDA for the twelve months ended December 31, 2024

     

    $

    3,684

    Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA)

     

    3.80x

    Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA)

     

    3.33x

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250206723660/en/

    Kerri Joseph

    IQVIA Investor Relations

    [email protected]

    +1.973.541.3558

    Get the next $IQV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    2/3/2025Buy → Neutral
    BTIG Research
    12/20/2024$250.00Overweight
    Stephens
    10/14/2024Buy
    Redburn Atlantic
    9/4/2024$275.00Outperform
    RBC Capital Mkts
    7/24/2024$266.00 → $242.00Buy → Hold
    Jefferies
    6/6/2024$270.00Buy
    Goldman
    More analyst ratings

    $IQV
    Leadership Updates

    Live Leadership Updates

    See more
    • IQVIA Appoints Richard Staub III President of Research & Development Solutions

      IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

      9/25/23 8:01:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

      IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

      6/7/22 8:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

      3/14/22 9:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Financials

    Live finance-specific insights

    See more
    • IQVIA Reports First-Quarter 2025 Results

      Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

      5/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

      4/21/25 4:15:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance

      Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency TAS Revenue of $1,658 million fo

      2/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Annual Health Care Conference on Tuesday, May 13, 2025, at 5:20 p.m. ET (2:20 p.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intellige

      5/7/25 4:15:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Reports First-Quarter 2025 Results

      Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

      5/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards

      IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Marie E. Lamont, head of Real World Solutions (Patient Insights, Experience and Registry Solutions), and Dr. Joanne Hackett, vice president, Health System Services (Europe, Middle East, Africa and South Asia), have been honored by the Healthcare Businesswomen's Association (HBA). Marie has been named a Luminary, and Joanne has been recognized as a Rising Star. Marie was honored for her significant contributions to IQVIA including increasing the patient voice in research and care delivery combined wit

      4/28/25 9:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IQVIA downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00

      4/25/25 8:30:17 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by Barclays with a new price target

      Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00

      4/10/25 8:49:29 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by BTIG Research

      BTIG Research downgraded IQVIA from Buy to Neutral

      2/3/25 8:45:01 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      2/7/25 7:03:59 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      8/15/24 7:57:23 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      2/14/24 4:11:54 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by IQVIA Holdings Inc. (Amendment)

      SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

      1/25/24 4:59:33 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    SEC Filings

    See more
    • SEC Form 10-Q filed by IQVIA Holdings Inc.

      10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)

      5/6/25 4:40:10 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      5/6/25 7:04:26 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      4/24/25 5:05:07 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Burt Carol

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      4/25/25 6:20:48 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Danhakl John G was granted 1,592 shares (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      4/25/25 6:20:03 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Fasano Jim

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      4/25/25 6:19:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care